Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Health Monitor.
Press releases published on July 30, 2025
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
GlobeNewswire
·
July 30, 2025
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today …
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
GlobeNewswire
·
July 30, 2025
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March …
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator
GlobeNewswire
·
July 30, 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major contract …
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
GlobeNewswire
·
July 30, 2025
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), supporting CETP inhibition as …
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
GlobeNewswire
·
July 30, 2025
Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
GlobeNewswire
·
July 30, 2025
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 30, 2025
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire
·
July 30, 2025
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its …
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 30, 2025
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
GlobeNewswire
·
July 30, 2025
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross-equity …
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
GlobeNewswire
·
July 30, 2025
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ …
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
GlobeNewswire
·
July 30, 2025
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care …
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
GlobeNewswire
·
July 30, 2025
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial …
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
GlobeNewswire
·
July 30, 2025
Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations. NEW YORK and …
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
GlobeNewswire
·
July 30, 2025
Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve® over 6–12 weeks Preclinical in vitro studies demonstrated >80% reduction in protease activity, …
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
GlobeNewswire
·
July 30, 2025
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study …
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
July 30, 2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple …
Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call
GlobeNewswire
·
July 30, 2025
DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today …
Immutep Quarterly Activities Report Q4 FY25
GlobeNewswire
·
July 30, 2025
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries Trial-in-Progress poster for TACTI- …
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
GlobeNewswire
·
July 30, 2025
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company …